Welcome back, everyone. We hope your weekend was restful and rejuvenating. Now, of course, the routine has returned. Meetings and deadlines, as usual, beckon. What better way to prepare than with a cup of stimulation? So please join us as we indulge. Meanwhile, here are a few items to help you get started. Hope your day goes well and stay in touch...
AstraZeneca Prostate Cancer Drug Fails Phase III (TheStreet)
Pfizer Plans More Partnerships In Asia (OutsourcingPharma)
Sanofi Keeps Genzyme Bid Steady, For Now (Reuters)
Merck To Hire 300 At No. Carolina Vaccine Plant (The Herald Sun)
Wyeth's Genetically Modified Baby Formula Causes Protest (Sydney Morning Herald)
European Rx Sales To Slow Due To Cost-Cutting (PharmaTimes)
Actelion Drug For Brain Hemorrhage Fails In Study (Bloomberg News)
Think Tank Urges Court To Rethink Lilly Patent Rejection (Economic Times)
1 Comment
Another "Frankenfood" scare with the genetically modified formula. 93% of soybean crops and 86% of corn crops are genetically modified in the US. No evidence of deleterious effects that I can find.